Mesa Laboratories Future Growth
Future criteria checks 4/6
Mesa Laboratories is forecast to grow earnings and revenue by 131.6% and 6.3% per annum respectively. EPS is expected to grow by 131.8% per annum. Return on equity is forecast to be 24.3% in 3 years.
Key information
131.6%
Earnings growth rate
131.8%
EPS growth rate
Life Sciences earnings growth | 17.9% |
Revenue growth rate | 6.3% |
Future return on equity | 24.3% |
Analyst coverage | Low |
Last updated | 09 Aug 2024 |
Recent future growth updates
Recent updates
A Piece Of The Puzzle Missing From Mesa Laboratories, Inc.'s (NASDAQ:MLAB) 27% Share Price Climb
Jul 29Is Now An Opportune Moment To Examine Mesa Laboratories, Inc. (NASDAQ:MLAB)?
May 03Is Mesa Laboratories (NASDAQ:MLAB) Using Too Much Debt?
Mar 15Mesa Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Feb 08Is Mesa Laboratories, Inc. (NASDAQ:MLAB) Trading At A 43% Discount?
Dec 05Is Mesa Laboratories (NASDAQ:MLAB) A Risky Investment?
Sep 28Estimating The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)
Aug 09We Think Mesa Laboratories (NASDAQ:MLAB) Is Taking Some Risk With Its Debt
Jun 28Investor Optimism Abounds Mesa Laboratories, Inc. (NASDAQ:MLAB) But Growth Is Lacking
May 31A Look At The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)
Apr 12Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?
Mar 13Estimating The Fair Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)
Dec 20Mesa Laboratories declares $0.16 dividend
Oct 03Mesa Laboratories: Softening Bottom Line Fundamentals, Fairly Priced
Sep 09Are Investors Undervaluing Mesa Laboratories, Inc. (NASDAQ:MLAB) By 41%?
Sep 06Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?
Aug 08Mesa Laboratories GAAP EPS of -$0.27 misses by $0.27, revenue of $50.45M misses by $1.72M
Aug 04Mesa Laboratories declares $0.16 dividend
Jul 07A Look At The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)
May 06Growth Investors: Industry Analysts Just Upgraded Their Mesa Laboratories, Inc. (NASDAQ:MLAB) Revenue Forecasts By 14%
Apr 09Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
3/31/2027 | 270 | 19 | 44 | 53 | 1 |
3/31/2026 | 248 | 11 | 39 | 45 | 3 |
3/31/2025 | 236 | 9 | 35 | 37 | 3 |
6/30/2024 | 224 | -250 | 41 | 45 | N/A |
3/31/2024 | 216 | -254 | 42 | 44 | N/A |
12/31/2023 | 213 | 1 | 41 | 44 | N/A |
9/30/2023 | 214 | -1 | 36 | 40 | N/A |
6/30/2023 | 219 | 2 | 36 | 41 | N/A |
3/31/2023 | 219 | 1 | 23 | 28 | N/A |
12/31/2022 | 222 | -1 | 20 | 25 | N/A |
9/30/2022 | 223 | -4 | 28 | 33 | N/A |
6/30/2022 | 200 | -2 | 23 | 27 | N/A |
3/31/2022 | 184 | 2 | 35 | 39 | N/A |
12/31/2021 | 163 | 8 | 39 | 43 | N/A |
9/30/2021 | 143 | 5 | 36 | 38 | N/A |
6/30/2021 | 139 | 4 | 42 | 44 | N/A |
3/31/2021 | 134 | 3 | 35 | 37 | N/A |
12/31/2020 | 130 | -2 | 31 | 32 | N/A |
9/30/2020 | 128 | -2 | 31 | 32 | N/A |
6/30/2020 | 121 | -2 | 27 | 29 | N/A |
3/31/2020 | 118 | 2 | 25 | 27 | N/A |
12/31/2019 | 110 | 5 | 27 | 28 | N/A |
9/30/2019 | 105 | 10 | 27 | 28 | N/A |
6/30/2019 | 104 | 8 | 24 | 25 | N/A |
3/31/2019 | 103 | 7 | 29 | 31 | N/A |
12/31/2018 | 104 | 10 | 28 | 30 | N/A |
9/30/2018 | 101 | -2 | 27 | 29 | N/A |
6/30/2018 | 99 | 0 | 28 | 30 | N/A |
3/31/2018 | 96 | -3 | N/A | 26 | N/A |
12/31/2017 | 94 | -4 | N/A | 17 | N/A |
9/30/2017 | 94 | 11 | N/A | 14 | N/A |
6/30/2017 | 95 | 11 | N/A | 7 | N/A |
3/31/2017 | 94 | 11 | N/A | 17 | N/A |
12/31/2016 | 94 | 12 | N/A | 14 | N/A |
9/30/2016 | 90 | 11 | N/A | 9 | N/A |
6/30/2016 | 88 | 10 | N/A | 18 | N/A |
3/31/2016 | 85 | 11 | N/A | 17 | N/A |
12/31/2015 | 78 | 9 | N/A | 15 | N/A |
9/30/2015 | 76 | 9 | N/A | 16 | N/A |
6/30/2015 | 73 | 10 | N/A | 13 | N/A |
3/31/2015 | 71 | 10 | N/A | 11 | N/A |
12/31/2014 | 68 | 11 | N/A | 9 | N/A |
9/30/2014 | 64 | 10 | N/A | 11 | N/A |
6/30/2014 | 58 | 9 | N/A | 10 | N/A |
3/31/2014 | 53 | 9 | N/A | 12 | N/A |
12/31/2013 | 50 | 8 | N/A | 12 | N/A |
9/30/2013 | 48 | 8 | N/A | 12 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MLAB is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).
Earnings vs Market: MLAB is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MLAB is expected to become profitable in the next 3 years.
Revenue vs Market: MLAB's revenue (6.3% per year) is forecast to grow slower than the US market (8.8% per year).
High Growth Revenue: MLAB's revenue (6.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MLAB's Return on Equity is forecast to be high in 3 years time (24.3%)